Starpharma Holdings Secures AU$32 Million Through Fully Underwritten Entitlement Offer; Shares Fall 16%

MT Newswires Live08-11 09:22

Starpharma Holdings (ASX:SPL) secured AU$32 million before costs through its fully underwritten 1-for-7.5 renounceable entitlement offer, with around 99% shareholder participation, including AU$5.4 million raised through the oversubscription facility, according to a Tuesday Australian bourse filing.

The company is expected to issue 56.1 million new shares on Tuesday, ranking equally with existing shares, per the filing.

Eligible shareholders will receive their full applications under the oversubscription facility, while proceeds from the sale of ineligible foreign shareholders' rights will be distributed on Friday, the filing said.

The proceeds will be used to fund the first-in-human and dose-escalation phases of a phase one study for a cancer treatment candidate, as well as advance additional oncology assets, the filing added.

The company's shares fell around 16% in recent Tuesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2658963272?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 09:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658963272","market":"nz","top_or_hot":-1,"title":"Starpharma Holdings Secures AU$32 Million Through Fully Underwritten Entitlement Offer; Shares Fall 16%","media":"MT Newswires Live","content":"<html><body><p> Starpharma Holdings (ASX:SPL) secured AU$32 million before costs through its fully underwritten 1-for-7.5 renounceable entitlement offer, with around 99% shareholder participation, including AU$5.4 million raised through the oversubscription facility, according to a Tuesday Australian bourse filing.</p><p>The company is expected to issue 56.1 million new shares on Tuesday, ranking equally with existing shares, per the filing.</p><p>Eligible shareholders will receive their full applications under the oversubscription facility, while proceeds from the sale of ineligible foreign shareholders' rights will be distributed on Friday, the filing said.</p><p>The proceeds will be used to fund the first-in-human and dose-escalation phases of a phase one study for a cancer treatment candidate, as well as advance additional oncology assets, the filing added.</p><p>The company's shares fell around 16% in recent Tuesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Starpharma Holdings Secures AU$32 Million Through Fully Underwritten Entitlement Offer; Shares Fall 16%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStarpharma Holdings Secures AU$32 Million Through Fully Underwritten Entitlement Offer; Shares Fall 16%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-11 09:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Starpharma Holdings (ASX:SPL) secured AU$32 million before costs through its fully underwritten 1-for-7.5 renounceable entitlement offer, with around 99% shareholder participation, including AU$5.4 million raised through the oversubscription facility, according to a Tuesday Australian bourse filing.</p><p>The company is expected to issue 56.1 million new shares on Tuesday, ranking equally with existing shares, per the filing.</p><p>Eligible shareholders will receive their full applications under the oversubscription facility, while proceeds from the sale of ineligible foreign shareholders' rights will be distributed on Friday, the filing said.</p><p>The proceeds will be used to fund the first-in-human and dose-escalation phases of a phase one study for a cancer treatment candidate, as well as advance additional oncology assets, the filing added.</p><p>The company's shares fell around 16% in recent Tuesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7501","symbol_name":"新冠治疗股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2658963272","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2658963272","pubTimestamp":1786411369,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Starpharma Holdings  secured AU$32 million before costs through its fully underwritten 1-for-7.5 renounceable entitlement offer, with around 99% shareholder participation, including AU$5.4 million raised through the oversubscription facility, according to a Tuesday Australian bourse filing.The company is expected to issue 56.1 million new shares on Tuesday, ranking equally with existing shares, per the filing.Eligible shareholders will receive their full applications under the oversubscription facility, while proceeds from the sale of ineligible foreign shareholders' rights will be distributed on Friday, the filing said.The proceeds will be used to fund the first-in-human and dose-escalation phases of a phase one study for a cancer treatment candidate, as well as advance additional oncology assets, the filing added.The company's shares fell around 16% in recent Tuesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7501":"新冠治疗股","BK7508":"医药生物股","BK7096":"制药","SPL.AU":"STARPHARMA HOLDINGS LTD"},"translate_title":"Starpharma Holdings 通过全额承销配股要约获得 3200 万澳元；股价下跌 16%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPL.AU":1},"content_text":"Starpharma Holdings (ASX:SPL) secured AU$32 million before costs through its fully underwritten 1-for-7.5 renounceable entitlement offer, with around 99% shareholder participation, including AU$5.4 million raised through the oversubscription facility, according to a Tuesday Australian bourse filing.The company is expected to issue 56.1 million new shares on Tuesday, ranking equally with existing shares, per the filing.Eligible shareholders will receive their full applications under the oversubscription facility, while proceeds from the sale of ineligible foreign shareholders' rights will be distributed on Friday, the filing said.The proceeds will be used to fund the first-in-human and dose-escalation phases of a phase one study for a cancer treatment candidate, as well as advance additional oncology assets, the filing added.The company's shares fell around 16% in recent Tuesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2658963272","isCrawlerRequest":true}